AAX Biotech to Showcase Novel Antibody Technology at PEGS Boston

AAX Biotech has announced its participation in the upcoming 22nd Annual PEGS Boston conference, scheduled for May 11-15, 2026. At the event, Dr. Ionut Gabriel Dumitru, the company's Head of R&D, will present its groundbreaking Opti-mAb® technology.

Opti-mAb® was developed to address the persistent challenge of scFv antibody instability. These antibodies are critical in rapidly expanding therapeutic areas, including CAR-T therapies and bispecific antibodies. However, their inherent instability has historically led to high development costs and limited their therapeutic performance.

According to AAX Biotech, Opti-mAb® significantly improves both the production yields and stability of scFv antibodies. Dr. Dumitru will detail these advancements in a poster titled “Opti-mAb®: a novel scFv format for improved therapies”.

Additionally, Dr. Dumitru will discuss Seqitope®, the company's high-resolution and high-throughput epitope mapping technology. This technology is designed to accelerate antibody discovery and de-risk lead candidate selection. AAX Biotech invites conference attendees to visit their poster at #209704 and engage in discussions about these innovative solutions.